Putting More Value Into Biopharmaceutical Value Assessments

2018-02-23T20:39:07-06:00January 4th, 2018|Viewpoints|

In a commentary for the Health Affairs Blog, Rena M. Conti, PhD, and IVI Executive Director, Darius Lakdawalla, argue that advancing the science of value assessment requires new assessment tools that are transparent and incorporate the perspectives of patients and insurance plan enrollees.

Read the full article here.